Thats what i got out of explanation from last call. Will anyone outside of the cydy management know the full extent… probably not. We know the FDA wanted RO from HIV bla. Data from the Cd-10 cd-12 longhaulers etc were already received by FDA. HIV Trail only one in Phase 3 and all the other Phase 2’s have already proven Safety and helped design best primary endpoint for future phase 3’s. I think it’s obviously a concern but not a major concern going forward as we have already moved on from Amarex. If we were still using them for future trials than i would be more concerned.